Contact Dermatitis Caused by Efinaconazole and Luliconazole.


Journal

Journal of Nippon Medical School = Nippon Ika Daigaku zasshi
ISSN: 1347-3409
Titre abrégé: J Nippon Med Sch
Pays: Japan
ID NLM: 100935589

Informations de publication

Date de publication:
30 Jun 2021
Historique:
pubmed: 31 8 2020
medline: 18 1 2022
entrez: 1 9 2020
Statut: ppublish

Résumé

We report a case of contact dermatitis caused by both efinaconazole, a topical triazole antifungal drug, and luliconazole, a topical imidazole antifungal drug. Positive patch test reactions were observed with efinaconazole and luliconazole. A patch test with lanoconazole also elicited a positive reaction. We hypothesized that structural similarity between luliconazole and lanoconazole led to cross-reaction, and that the dithiolane ring common to both drugs or the structure of the vinyl imidazole with a dithiolane ring could be the antigenic determinant. Since efinaconazole and luliconazole have no common structures, patients could be sensitized to both drugs separately. The antigenic determinant of efinaconazole is unknown. However, the chemical formula of ravuconazole, an oral triazole antifungal drug, is similar to that of efinaconazole. Clinicians should carefully consider potential cross-reactivity between these drugs.

Identifiants

pubmed: 32863343
doi: 10.1272/jnms.JNMS.2021_88-312
doi:

Substances chimiques

Antifungal Agents 0
Epitopes 0
Imidazoles 0
Triazoles 0
efinaconazole J82SB7FXWB
luliconazole RE91AN4S8G

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

253-257

Auteurs

Kazuhisa Fujimoto (K)

Department of Dermatology, Nippon Medical School.

Hanao Yamaguchi (H)

Department of Dermatology, Nippon Medical School.

Yohei Otsuka (Y)

Department of Dermatology, Nippon Medical School.

Nobuko Mayumi (N)

Department of Dermatology, Nippon Medical School.

Hidehisa Saeki (H)

Department of Dermatology, Nippon Medical School.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH